News

June 2024

Zimbabwe applies for PIC/S pre-accession

Geneva, 6 June 2024:

On 20 October 2023, the Medicines Control Authority of Zimbabwe (MCAZ) applied for PIC/S pre-accession. The pre-accession application was considered complete on 6 December 2023. The Rapporteur is in the process of being appointed by written procedure.

November 2026

Revision of the PIC Scheme (PIC/S 1/95 (Rev. 7))

Geneva, 12 November 2026:

The PIC/S Committee adopted the revised Pharmaceutical Inspection Co-operation Scheme (PIC/S 1/95 (Rev. 7)) at its meeting on 2 November 2026 in Istanbul, Türkiye. The revised Scheme entered into force on the same date.

The PIC Scheme serves as the legal basis and institutional framework for PIC/S as a non-profit association established under Swiss law. It governs the organisation and functioning of PIC/S and establishes a legally non-binding arrangement for co-operation between its Members. Unlike the Pharmaceutical Inspection Convention of 1970, which is an international treaty providing for mutual recognition of inspections, the PIC Scheme offers a flexible framework for international regulatory co-operation. Established in 1995, PIC/S core mission is to lead the international development, implementation, and maintenance of harmonised GMP standards and quality systems of Inspectorates in the field of medicinal products.

The previous revision of the PIC Scheme was adopted in November 2019. The current revision introduces significant updates to modernise the institutional and governance framework of PIC/S, reflect the evolution of its activities and strengthen its capacity to fulfil its public health mission.

The main changes introduced by Revision 7 include:

  • Reinforcing PIC/S' mission and strategic objectives: explicitly placing the protection of public health at the centre of its mission and strengthening the emphasis on inspection reliance, global regulatory convergence and co-operation with international regulatory and harmonisation bodies.

  • Clarifying membership categories and requirements: introducing Participating Organisations as a distinct membership category, subject to specific PIC/S requirements, and updating relevant definitions and terminology.

  • Strengthening training and knowledge sharing: reinforcing the role of the PIC/S Inspectorates' Academy (PIA) in promoting harmonised training, consistent inspector qualification processes and inspection excellence, while supporting structured knowledge transfer and capacity building.

  • Modernising governance arrangements: clarifying the respective responsibilities, delegation of powers and oversight arrangements of the PIC/S Committee, Executive Bureau and Secretariat, including the management of the Secretariat.

  • Enhancing financial governance and accountability: updating provisions relating to financial oversight, the review of annual accounts and auditing arrangements, in accordance with the applicable Swiss legal framework.

The revised PIC Scheme (PIC/S 1/95 (Rev. 7)) is available on the PIC/S website under Publications Link.

October 2026

Adoption and Entry into force of PIC/S Recommendation (PI 058-1) - Interpretation of the most important changes in the Annex 1 on the Manufacture of Sterile Products (2022)

Geneva, 28 October 2026

PIC/S has published the Recommendation PI 058-1 - Interpretation of the most important changes in the Annex 1 on the Manufacture of Sterile Products (2022).

This document was prepared by a sub-group of experts from the PIC/S-EMA-WHO Joint Implementation Working Group (A1IWG) bringing together experts from WHO, EMA, and PIC/S Participating Authorities. The A1IWG was established in January 2024 following the entry into force on 25 August 2023 of the revised Annex 1 on “sterile manufacturing of the PIC/S GMP Guide”.

The document, formally adopted by PIC/S, EMA and WHO, was presented to selected Stakeholders during a Briefing Meeting (Webinar) hosted by the EMA on 22 October 2026.

PI 058-1 enters into force on 28 October 2026.

To download PI 058-1, please consult the page “Publication”

September 2026

Revision of PIC/S GMP Guide (PE 009-18)

Geneva, 23 September 2026:

The PIC/S GMP Guide to Good Manufacturing Practice (GMP) for Medicinal Products has been revised to include the revised Annex 19 (Reference and Retention Samples).

The revision of PIC/S Annex 19 primarily concerns Section 9, which addresses reference and retention samples for parallel imported, parallel distributed, and parallel traded products. The note clarifying that Section 9 applies only where local legislation covers parallel imported, parallel distributed, or parallel traded products — present in the previous version of the PIC/S GMP Guide (PE 009-17) — has been retained in the current version (PE 009-18).

This update aligns with the Co-operation Agreement between PIC/S and the EMA, which mandates the harmonisation of PIC/S and EU GMP Guides. The aim is to maintain equivalent GMP standards, thereby facilitating the exchange and use of information concerning the manufacture of medicinal products, in line with PIC/S' mission to lead the international development, implementation, and maintenance of harmonised GMP standards and quality systems for inspectorates in the field of medicinal products.

The revised Annex 19 was successfully adopted by the PIC/S Committee by written procedure on 22 September 2026. 

The revised GMP Guide (PE 009-18), with the revised Annex 19 will enter into force on 24 September 2026. This coincides with the entry into force of the revised Annex 19 in the EU following the publication by the European Commission of the revised Annex 19 on Eudralex Volume 4 on 23 June 2026.

All non-EEA Participating Authorities of PIC/S and Applicants have been invited to transpose Annex 19 of the PIC/S GMP Guide into their own GMP Guides.

To download the revised GMP Guide (PE 009-18), please consult the “Publications” page.

July 2026

Revision of PIC/S Recommendations on Qualification and Validation (PI 006-4)

Geneva, 30 July 2026

PIC/S has published the revised PIC/S Recommendations on Qualification and Validation (PI 006-4).

These Recommendations have been revised by a dedicated PIC/S Working Group, successively chaired by Norman Gray (UK / MHRA) and subsequently jointly chaired by Kevin O’Donnell (Ireland / HPRA) and Rebecca Dowd (USA / US FDA). They supersede the PIC/S Recommendations on Validation Master Plan; Installation and Operational Qualification; Non-Sterile Process Validation; and Cleaning Validation (PI 006-3).

PI 006-4 will enter into force on 1 October 2026.

To download the revised Recommendations document, please consult the page “Publications”.

July 2026

2026 PIC/S Seminar (Istanbul / Türkiye)

Geneva, 28 July 2026: 

Registrations for the 2026 PIC/S Seminar on “Digital Transformation in GMP” which will be hosted by Türkiye / TMMDA from 4-6 November 2026 are now open (for Medicines Regulatory Authorities only). Deadline for registrations is 31 August 2026 (early-bird) and 23 October 2026 (standard).

For more information,  please contact the PIC/S Secretariat.

July 2026

United Arab Emirates applies for PIC/S Pre-Accession

Geneva, 28 July 2026:

On 15 July 2026, a Rapporteur was appointed by written procedure for the pre-accession application of Emirates Drug Establishment (EDE), for which a pre-accession application was received on 5 March 2026.

In line with the revised PIC/S Guidelines for the Pre-Accession Procedure, the designation of the Rapporteur marks the start of the pre-accession process.

July 2026

Uzbekistan applies for PIC/S membership

Geneva, 28 July 2026:

On 17 December 2025, the State Entity “Center of Good Practices” of the Pharmaceutical Industry Development Agency under the Ministry of Health of the Republic of Uzbekistan and the State Institution “Center for Pharmaceutical Products Safety” under the Ministry of Health of the Republic of Uzbekistan, submitted a joint membership application to PIC/S.

The application received was completed on 15 January 2026, further to which the Rapporteurs and Audit Team are in the process of being appointed by written procedure.

July 2026

Concept paper on the revision of EU-PIC/S GMP Annex 15 (Qualification and validation) - Corrigendum

Geneva, 16 July 2026:

The joint EMA - PIC/S drafting group has developed a concept paper on the revision of the Annex 15 (Qualification and validation) of the EU - PIC/S GMP Guide.

This concept paper aims to outline the rationale, objectives, and proposed changes for updating the Annex 15 - Qualification and validation, of the Good Manufacturing Practice (GMP) Guide, that is common to the Member States of the European Union (EU) / European Economic Area (EEA), as well as to the Participating Authorities (PAs) of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The aim of the revision is to extend the scope of the annex to active substances manufacturers and to consider the revision of ICH Guideline Q9 (R1) on quality risk management.

This concept paper was submitted to a joint EMA - PIC/S public consultation and comments have been collected until 9 April 2026. Following the public consultation, the initial timetable has been revised, and only this section has been updated accordingly.

The revised Concept Paper can be downloaded on the PIC/S website (link), as well as on the EMA website (link).

February 2026

Concept paper on the revision of EU-PIC/S GMP Annex 6 - Manufacture of medicinal gases

Geneva, 12 February 2026:

The joint EMA - PIC/S drafting group has developed a concept paper on the revision of the Annex 6 (Manufacture of medicinal gases) of the EU-PIC/S GMP Guide.

This concept paper aims to outline the rationale, objectives, and proposed changes for updating the Annex 6 - Manufacture of medicinal gases, of the Good Manufacturing Practice (GMP) Guide, that is common to the Member States of the European Union (EU) / European Economic Area (EEA), as well as to the Participating Authorities (PAs) of the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

The aim of the revision is to carry out a limited review and update of the guideline to reflect industry’s current practices, including the use of new technologies and computerized systems.

This concept paper is submitted to a joint EMA - PIC/S public consultation from 11 February 2026 until 11 April 2026 and can be downloaded on the PIC/S website (link) as well as on the EMA website (link).

Comments should be submitted via the EU Survey tool (link) in accordance with the PIC/S - EMA Harmonised Consultation Procedure.

February 2026

Concept paper on the revision of EU-PIC/S GMP Annex 15 (Qualification and validation)

Geneva, 10 February 2026:

The joint EMA - PIC/S drafting group has developed a concept paper on the revision of the Annex 15 (Qualification and validation) of the EU - PIC/S GMP Guide.

This concept paper aims to outline the rationale, objectives, and proposed changes for updating the Annex 15 - Qualification and validation, of the Good Manufacturing Practice (GMP) Guide, that is common to the Member States of the European Union (EU) / European Economic Area (EEA), as well as to the Participating Authorities (PAs) of the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

The aim of the revision is to extend the scope of the annex to active substances manufacturers and to consider the revision of ICH Guideline Q9 (R1) on quality risk management.

This concept paper is submitted to a joint EMA - PIC/S public consultation from 9 February 2026 until 9 April 2026 and can be downloaded on the PIC/S website (link) as well as on the EMA website (link).

Comments should be submitted via the EU Survey tool (link) in accordance with the PIC/S - EMA Harmonised Consultation Procedure.

February 2026

Kazakhstan applies for PIC/S membership

Geneva, 10 February 2026:

On 20 March 2025, Kazakhstan’s Committee for Medical and Pharmaceutical Control of the Ministry of Healthcare of the Republic of Kazakhstan (“CMPC”) and the State Enterprise on the right of economic management “National center for expertise of medicines and medical devices” (“NCEM”) of the Committee applied for PIC/S membership.

The application request was confirmed as complete at the PIC/S Committee meeting in Hong Kong (Hong Kong SAR, China) on 3-4 November 2025, further to which a Rapporteur and Co-Rapporteur were appointed.

February 2026

Ghana applies for PIC/S pre-accession

Geneva, 3 February 2026: 

The Ghana Food and Drugs Authority has applied for PIC/S pre-accession.

The pre-accession process started on 4 November 2025 following the appointment of a Rapporteur, which marks the start of the pre-accession process under the revised PIC/S pre-accession procedure.

January 2026

Jordan / JFDA joins PIC/S

Geneva, 1 January 2026:

On 1 January 2026, the Jordan Food & Drug Administration (JFDA) became the 57th PIC/S Participating Authority.

JFDA submitted a complete membership application in January 2021, after successfully completing the pre-accession process. A paper assessment was carried out followed by an on-site assessment visit, which took place in April 2025. The Audit team recommended to the Committee to accept the PIC/S membership application of JFDA. After endorsement by the PIC/S Sub-Committee on Compliance (SCC), the PIC/S Committee then unanimously decided at its meeting in Hong Kong on 3-4 November 2025 on the participation of JFDA in PIC/S as of 1 January 2026.